Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

RGEN

Repligen Corp

Apr 10 • 04:00PM ET

120.10

+0.32 0.27 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: BIO TMO DHR WAT ILMN BRKR TECH MTD QGEN A

| Held by: VTI IJH VB VBK VXF FBT IBB MDY SPMD IWR

Index	-	P/E	138.94	EPS (ttm)	0.86	Insider Own	5.44%	Shs Outstand	56.33M	Perf Week	1.97%
Market Cap	6.77B	Forward P/E	47.55	EPS next Y	2.53	Insider Trans	-1.75%	Shs Float	53.26M	Perf Month	0.73%
Enterprise Value	6.69B	PEG	1.94	EPS next Q	0.38	Inst Own	111.13%	Short Float	10.43%	Perf Quarter	-27.83%
Income	48.89M	P/S	9.16	EPS this Y	16.39%	Inst Trans	3.19%	Short Ratio	6.62	Perf Half Y	-20.36%
Sales	738.26M	P/B	3.21	EPS next Y	26.91%	ROA	1.69%	Short Interest	5.56M	Perf YTD	-26.71%
Book/sh	37.39	P/C	8.81	EPS next 5Y	24.45%	ROE	2.40%	52W High	175.77 -31.67%	Perf Year	4.26%
Cash/sh	13.63	P/FCF	73.79	EPS past 3/5Y	-35.60% -4.91%	ROIC	1.76%	52W Low	109.66 9.52%	Perf 3Y	-27.41%
Dividend Est.	-	EV/EBITDA	37.75	Sales past 3/5Y	-2.70% 15.05%	Gross Margin	47.28%	Volatility	3.33% 3.97%	Perf 5Y	-41.73%
Dividend TTM	-	EV/Sales	9.06	EPS Y/Y TTM	291.20%	Oper. Margin	6.90%	ATR (14)	5.35	Perf 10Y	333.57%
Dividend Ex-Date	-	Quick Ratio	7.12	Sales Y/Y TTM	16.36%	Profit Margin	6.62%	RSI (14)	49.43	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	8.37	EPS Q/Q	138.81%	SMA20	3.25%	Beta	1.17	Target Price	184.71
Payout	0.00%	Debt/Eq	0.33	Sales Q/Q	18.12%	SMA50	-5.72%	Rel Volume	0.64	Prev Close	119.78
Employees	2000	LT Debt/Eq	0.32	Earnings	Feb 24 BMO	SMA200	-13.11%	Avg Volume	839.87K	Price	120.10
IPO	Apr 29, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.46% 2.60%	Trades		Volume	540,287	Change	0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-25	Initiated	HSBC Securities	Buy	$150
Sep-22-25	Upgrade	Evercore ISI	In-line → Outperform	$155
Jul-22-25	Resumed	Stephens	Overweight	$160
Jun-24-25	Initiated	Barclays	Overweight	$150
Apr-29-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$160
Mar-18-25	Initiated	Evercore ISI	In-line	$155
Feb-10-25	Initiated	TD Cowen	Buy	$200
Dec-17-24	Initiated	Canaccord Genuity	Hold	$165
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Aug-28-24	Initiated	Wells Fargo	Overweight	$180
Jun-26-24	Upgrade	Deutsche Bank	Hold → Buy	$180 → $155
Jun-18-24	Initiated	Guggenheim	Neutral
Dec-04-23	Downgrade	The Benchmark Company	Buy → Hold
Jul-20-23	Initiated	Wells Fargo	Overweight	$185
Jul-05-23	Resumed	JP Morgan	Overweight	$220
Mar-28-23	Initiated	The Benchmark Company	Buy	$230
Dec-14-22	Initiated	Deutsche Bank	Hold	$180
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform	$190
Jul-20-22	Initiated	UBS	Buy	$213
Oct-14-21	Initiated	Exane BNP Paribas	Outperform	$330

Show Previous Ratings

Mar-05-26 07:30AM	Repligen Corporation to Present at Upcoming March Conferences (GlobeNewswire)
Mar-02-26 11:06PM	3 Reasons to Avoid RGEN and 1 Stock to Buy Instead (StockStory)
Feb-25-26 01:47PM	Analyst Report: Repligen Corporation (Morningstar Research)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
Feb-24-26 04:32PM	Repligen Corporation Q4 2025 Earnings Call Summary (Moby)
04:02PM	Loading…
04:02PM	Repligen Corp (RGEN) Q4 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ... (GuruFocus.com)
12:49PM	Repligen Q4 Earnings Call Highlights (MarketBeat)
09:40AM	Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:47AM	Repligen: Q4 Earnings Snapshot (Associated Press Finance)
07:37AM	Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations (StockStory)
07:30AM	Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
Feb-22-26 10:13PM	Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-19-26 11:43PM	2 of Wall Street's Favorite Stocks Worth Investigating and 1 We Avoid (StockStory)
Feb-10-26 07:30AM	Repligen to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-06-26 08:16AM	What Makes Repligen Corporation (RGEN) an Investment Choice? (Insider Monkey)
08:04PM	Loading…
Feb-04-26 08:04PM	Analyst Report: Repligen Corporation (Morningstar Research)
Jan-26-26 11:01PM	3 Reasons to Sell RGEN and 1 Stock to Buy Instead (StockStory)
Jan-22-26 09:52PM	UBS Tags Repligen (RGEN) as Bioprocessing Leader for 2026, Cites 20% Order Growth and Reshoring Tailwinds (Insider Monkey)
Jan-14-26 02:15PM	Why Repligen (RGEN) Shares Are Sliding Today (StockStory)
Jan-06-26 07:30AM	Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair (GlobeNewswire)
Dec-18-25 07:30AM	Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-17-25 08:35AM	Here's Why Sands Capital Global Growth Fund Decided to Sell Repligen Corporation (RGEN) (Insider Monkey)
Dec-16-25 07:30AM	Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows (GlobeNewswire)
Dec-07-25 11:35PM	1 Volatile Stock to Target This Week and 2 We Turn Down (StockStory)
Dec-03-25 11:30AM	Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? (Zacks)
Nov-26-25 07:30AM	Repligen Corporation to Present at Evercore Healthcare Conference (GlobeNewswire)
Nov-21-25 07:09PM	Analyst Report: Repligen Corporation (Morningstar Research) +5.28%
06:36PM	Why Repligen (RGEN) Stock Is Trading Up Today (StockStory)
Nov-06-25 10:31PM	Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN) (StockStory)
Nov-04-25 07:30AM	Repligen Corporation to Present at Upcoming November Conferences (GlobeNewswire)
12:32AM	Loading…
12:32AM	5 Revealing Analyst Questions From Repligen's Q3 Earnings Call (StockStory)
Oct-30-25 07:45PM	Analyst Report: Repligen Corporation (Morningstar Research)
Oct-29-25 01:13PM	Analyst Report: Repligen Corporation (Morningstar Research)
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:40AM	RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset (StockStory)
Oct-28-25 02:35PM	Why Repligen (RGEN) Shares Are Trading Lower Today (StockStory) -5.92%
08:45AM	Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
08:01AM	Repligen's (NASDAQ:RGEN) Q3 Sales Beat Estimates (StockStory)
07:40AM	Repligen: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance (GlobeNewswire)
Oct-27-25 09:22AM	Earnings To Watch: Repligen Corp (RGEN) Reports Q3 2025 Result (GuruFocus.com)
Oct-26-25 11:13PM	Repligen Earnings: What To Look For From RGEN (StockStory)
Oct-23-25 07:15PM	Analyst Report: Repligen Corporation (Morningstar Research)
10:00AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 11:40AM	ALKS vs. RGEN: Which Stock Is the Better Value Option? (Zacks)
10:00AM	Earnings Preview: Repligen (RGEN) Q3 Earnings Expected to Decline (Zacks)
Oct-15-25 07:30AM	Repligen to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-09-25 07:46AM	Is Repligen (RGEN) The Best Healthcare Stock to Buy Now? (Insider Monkey)
Oct-01-25 12:20PM	Why Is Repligen (RGEN) Stock Soaring Today (StockStory) +9.08%
Sep-30-25 04:05PM	Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know (StockStory) +7.72%
Sep-24-25 12:04AM	3 Reasons to Sell RGEN and 1 Stock to Buy Instead (StockStory)
Sep-22-25 11:31PM	Drug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN) (StockStory)
Sep-16-25 02:51PM	Repligen (RGEN) Stock Is Up, What You Need To Know (StockStory) +5.28%
Sep-12-25 02:26PM	Why Repligen (RGEN) Stock Is Down Today (StockStory)
Aug-22-25 03:40PM	Repligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To Know (StockStory)
07:30AM	Repligen Corporation to Present at Upcoming September Conferences (GlobeNewswire)
Aug-20-25 08:42AM	Do Options Traders Know Something About Repligen Stock We Don't? (Zacks)
Aug-12-25 12:53AM	RGEN Q2 Deep Dive: Chromatography and Filtration Drive Growth, Guidance Lifted Amid New Modalities Uncertainty (StockStory) +8.51%
12:35AM	5 Must-Read Analyst Questions From Repligen's Q2 Earnings Call (StockStory)
Aug-07-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jul-31-25 07:30AM	Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization (GlobeNewswire)
Jul-29-25 11:52PM	Analyst Report: Repligen Corporation (Morningstar Research)
02:26PM	Why Repligen (RGEN) Stock Is Up Today (StockStory)
08:45AM	Repligen (RGEN) Lags Q2 Earnings Estimates (Zacks)
08:09AM	Repligen's (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic (StockStory)
07:41AM	Repligen: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance (GlobeNewswire)
Jul-28-25 09:22AM	Repligen Corp (RGEN) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-27-25 11:06PM	Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
Jul-22-25 09:40AM	Netflix downgraded, Intel initiated: Wall Street's top analyst calls (The Fly)
Jul-21-25 09:45AM	Here's Why Repligen (RGEN) is a Strong Growth Stock (Zacks)
Jul-18-25 03:11PM	Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know (StockStory) -6.28%
12:03AM	3 Reasons RGEN is Risky and 1 Stock to Buy Instead (StockStory)
Jul-17-25 07:30AM	Repligen to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 02:18PM	5 Insightful Analyst Questions From Repligen's Q1 Earnings Call (StockStory)
Jun-16-25 08:00AM	908 Devices Appoints Christopher D. Brown to its Board of Directors (Business Wire)
Jun-04-25 11:36PM	Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
Jun-03-25 11:32PM	Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers (StockStory)
Jun-02-25 01:36PM	Do Options Traders Know Something About Repligen (RGEN) Stock We Don't? (Zacks)
May-29-25 11:30AM	Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? (Zacks)
May-27-25 07:30AM	Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report (GlobeNewswire)
May-22-25 07:30AM	Repligen Corporation to Present at William Blair Growth Conference (GlobeNewswire)
May-09-25 12:36AM	1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar (StockStory)
May-07-25 07:30AM	Repligen Corporation to Present at Upcoming May Investor Conferences (GlobeNewswire)
May-02-25 11:40AM	QGEN or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
08:18AM	Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare (Insider Monkey)
May-01-25 12:11PM	Jim Cramer on Repligen Corporation (RGEN): 'I'm Not Quite Ready to Stick My Neck Out on This One' (Insider Monkey)
Apr-30-25 04:19PM	RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty (StockStory)
10:55AM	Analyst Report: Repligen Corporation (Morningstar Research)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
03:09AM	Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-29-25 11:50PM	Q1 2025 Repligen Corp Earnings Call (Thomson Reuters StreetEvents)
12:58PM	Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:45AM	Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates (Zacks)
08:05AM	Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations (StockStory)
07:45AM	Repligen: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Repligen Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-28-25 07:08PM	What To Expect From Repligen Corp (RGEN) Q1 2025 Earnings (GuruFocus.com)
03:08AM	Repligen (RGEN) Q1 Earnings: What To Expect (StockStory)
Apr-25-25 09:16AM	3 Healthcare Stocks That Concern Us (StockStory)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAWES KAREN A	Director	Dec 17 '25	Sale	161.00	275	44,275	91,821	Dec 18 04:30 PM
MUIR GLENN P	Director	Dec 16 '25	Option Exercise	26.12	3,366	87,920	36,622	Dec 17 04:30 PM
DAWES KAREN A	Director	Dec 17 '25	Proposed Sale	161.00	275	44,275		Dec 17 04:28 PM
Loeillot Olivier	Chief Executive Officer	Nov 25 '25	Sale	170.00	7,041	1,196,970	35,898	Nov 26 04:30 PM
Loeillot Olivier	Officer	Nov 25 '25	Proposed Sale	170.00	7,041	1,196,970		Nov 25 12:06 PM
Bylund James	Chief Operating Officer	Nov 18 '25	Sale	151.21	2,191	331,301	21,520	Nov 19 04:30 PM
Bylund James	Officer	Nov 18 '25	Proposed Sale	151.21	2,191	331,304		Nov 18 04:10 PM
Hunt Anthony	Director	Nov 13 '25	Option Exercise	33.87	2,952	99,984	83,695	Nov 14 04:30 PM
Hunt Anthony	Director	Nov 13 '25	Sale	154.61	20,000	3,092,278	80,743	Nov 14 04:30 PM
Hunt Anthony	Director	Nov 12 '25	Option Exercise	33.87	25,000	846,750	125,743	Nov 13 04:30 PM
Hunt Anthony	Director	Nov 12 '25	Sale	156.88	25,000	3,921,940	100,743	Nov 13 04:30 PM
Hunt Anthony	Director	Nov 13 '25	Proposed Sale	154.62	20,000	3,092,327		Nov 13 04:11 PM
Hunt Anthony	Director	Nov 12 '25	Proposed Sale	156.88	25,000	3,921,981		Nov 12 04:37 PM
Hunt Anthony	Director	Sep 10 '25	Option Exercise	33.87	20,000	677,400	129,854	Sep 11 02:55 PM
Hunt Anthony	Director	Sep 10 '25	Sale	120.52	29,111	3,508,389	100,743	Sep 11 02:55 PM
Hunt Anthony	Director	Sep 10 '25	Proposed Sale	120.52	29,111	3,508,378		Sep 10 04:22 PM
Madaus Martin D	Director	Aug 08 '25	Buy	112.13	1,800	201,830	1,800	Aug 12 12:47 PM
Hunt Anthony	Director	May 15 '25	Sale	123.71	26,447	3,271,688	109,854	May 16 03:02 PM
Hunt Anthony	Director	May 15 '25	Proposed Sale	128.34	26,447	3,394,208		May 15 10:25 AM

ASRT Assertio Holdings Inc daily Stock Chart

Peers: SFM OIS DCTH HRTX PBPB MYE OPI NUS FET TSE

| Held by: VTI VXF BSVO DFAS DFSV

Index	-	P/E	-	EPS (ttm)	-4.92	Insider Own	2.65%	Shs Outstand	6.42M	Perf Week	-6.19%
Market Cap	116.14M	Forward P/E	40.95	EPS next Y	0.44	Insider Trans	-4.98%	Shs Float	6.27M	Perf Month	56.70%
Enterprise Value	92.98M	PEG	-	EPS next Q	-2.10	Inst Own	33.85%	Short Float	4.81%	Perf Quarter	93.56%
Income	-30.38M	P/S	0.98	EPS this Y	73.47%	Inst Trans	5.58%	Short Ratio	3.17	Perf Half Y	35.29%
Sales	118.71M	P/B	1.23	EPS next Y	134.99%	ROA	-11.01%	Short Interest	0.30M	Perf YTD	98.68%
Book/sh	14.63	P/C	1.83	EPS next 5Y	-	ROE	-28.25%	52W High	20.45 -11.88%	Perf Year	99.23%
Cash/sh	9.84	P/FCF	-	EPS past 3/5Y	- 21.69%	ROIC	-22.67%	52W Low	8.18 120.39%	Perf 3Y	-79.74%
Dividend Est.	-	EV/EBITDA	7.28	Sales past 3/5Y	-8.75% 2.24%	Gross Margin	44.92%	Volatility	3.04% 7.36%	Perf 5Y	-50.77%
Dividend TTM	-	EV/Sales	0.78	EPS Y/Y TTM	-39.97%	Oper. Margin	-14.51%	ATR (14)	0.98	Perf 10Y	-98.23%
Dividend Ex-Date	-	Quick Ratio	1.51	Sales Y/Y TTM	-5.00%	Profit Margin	-25.59%	RSI (14)	63.28	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.70	EPS Q/Q	-12.91%	SMA20	8.12%	Beta	0.49	Target Price	27.25
Payout	-	Debt/Eq	0.43	Sales Q/Q	-57.92%	SMA50	30.48%	Rel Volume	3.92	Prev Close	18.02
Employees	53	LT Debt/Eq	0.43	Earnings	Mar 16 AMC	SMA200	49.41%	Avg Volume	95.12K	Price	18.02
IPO	Dec 02, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	40.43% 118.45%	Trades		Volume	372,473	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Downgrade	H.C. Wainwright	Buy → Neutral	$18
Jul-26-24	Initiated	Maxim Group	Buy	$3
Jul-03-24	Initiated	H.C. Wainwright	Buy	$4
Nov-07-22	Initiated	Lake Street	Buy	$7
Nov-30-18	Downgrade	Mizuho	Buy → Neutral

Apr-08-26 04:10PM	Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN and Additional Products from Assertio (Business Wire)
04:04PM	Assertio Announces Agreement to be Acquired by Garda Therapeutics (Business Wire)
Mar-16-26 11:00PM	Assertio Holdings Inc (ASRT) Q4 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +6.20%
08:13PM	Assertio Holdings, Inc. Q4 2025 Earnings Call Summary (Moby)
04:30PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Assertio Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Mar-05-26 12:37PM	Immunovant Stock Surges 17% in 3 Months: What's Driving It? (Zacks)
08:24AM	AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know (Zacks)
Mar-04-26 09:40AM	Is Assertio (ASRT) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-03-26 04:30PM	Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 (Business Wire)
Mar-02-26 09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
Feb-27-26 12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks)
12:06PM	PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View (Zacks)
07:44AM	Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-26 09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
09:02AM	Loading…
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
Feb-24-26 11:31AM	SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus (Zacks)
Feb-23-26 10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
Feb-16-26 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Feb-12-26 08:10AM	Zoetis (ZTS) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-06-26 11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks) +9.64%
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
06:28AM	Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:55AM	Wall Street Analysts See a 230.56% Upside in Assertio (ASRT): Can the Stock Really Move This High? (Zacks)
10:24AM	Loading…
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-16-26 09:55AM	Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet (Zacks)
Jan-14-26 09:40AM	Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-12-26 04:15PM	Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements (Business Wire) +10.89%
Jan-09-26 01:45PM	Assertio Announces Publication of Rolvedon Same-Day Dosing Clinical Trial (Business Wire)
Dec-22-25 04:30PM	Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split (Business Wire) -9.81%
Nov-11-25 04:01AM	Assertio Holdings Inc (ASRT) Q3 2025 Earnings Call Highlights: Impressive Growth Amid Market ... (GuruFocus.com) +14.89%
Nov-10-25 05:45PM	Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +5.33%
04:41PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance)
04:13PM	Assertio Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-06-25 08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
Oct-28-25 09:15AM	Assertio Announces Leadership Transition (GlobeNewswire)
Sep-23-25 05:04AM	New Strong Sell Stocks for September 23rd (Zacks)
Sep-19-25 06:23AM	New Strong Sell Stocks for September 19th (Zacks) -7.22%
Sep-16-25 04:59AM	New Strong Sell Stocks for September 16th (Zacks)
Sep-15-25 09:00AM	Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN (clobazam) Oral Film, CIV (GlobeNewswire)
Sep-10-25 07:30AM	Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN at upcoming 150th Annual Meeting of the American Neurological Association (GlobeNewswire)
Sep-03-25 08:15AM	Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 (GlobeNewswire)
Aug-26-25 06:17AM	New Strong Sell Stocks for August 26th (Zacks)
Aug-12-25 03:06AM	Assertio Holdings Inc (ASRT) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +13.85%
Aug-11-25 06:55PM	Assertio (ASRT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:54PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:31AM	Assertio Holdings Inc (ASRT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-06-25 03:41PM	Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors (PR Newswire)
08:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:30AM	Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-08-25 06:28AM	New Strong Sell Stocks for July 8th (Zacks)
Jun-30-25 06:03AM	New Strong Sell Stocks for June 30th (Zacks)
Jun-25-25 06:26AM	New Strong Sell Stocks for June 25th (Zacks)
Jun-18-25 05:08AM	New Strong Sell Stocks for June 18th (Zacks)
May-19-25 04:10PM	Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025 (GlobeNewswire) +6.77%
May-13-25 05:38AM	Q1 2025 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Assertio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-09-25 09:48AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-25 08:15AM	Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -6.46%
Apr-07-25 09:17AM	Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? (Zacks) -6.19%
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE)
Mar-20-25 09:10AM	Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 (GlobeNewswire)
Mar-13-25 12:58PM	Q4 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.46%
03:08AM	Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Highlights: Strategic Growth Amidst Challenges (GuruFocus.com)
Mar-12-25 04:30PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-05-25 04:05PM	Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 (GlobeNewswire) +6.49%
Jan-03-25 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-17-24 08:30AM	Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors (GlobeNewswire)
Dec-13-24 08:00AM	Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study (GlobeNewswire)
Dec-12-24 08:00AM	Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO (GlobeNewswire)
Dec-06-24 07:00AM	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer (GlobeNewswire)
Nov-15-24 09:00AM	Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio (Business Wire)
Nov-12-24 09:41AM	Q3 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.89%
Nov-11-24 04:09PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance) +8.82%
04:02PM	Assertio Reports Third Quarter 2024 Financial Results (GlobeNewswire)
03:41PM	Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio (Business Wire)
07:30AM	Assertio Provides Response to Letter from Short-seller (GlobeNewswire)
Nov-08-24 09:00AM	Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud (Business Wire) -15.84%
07:06AM	Assertio Holdings Inc (ASRT) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Oct-30-24 08:00AM	Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024 (GlobeNewswire)
Oct-11-24 08:00AM	Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 (GlobeNewswire)
Oct-09-24 05:18PM	Assertio Holdings Inc (ASRT) Q2 2024 Earnings Call Highlights: Navigating Sales Challenges and ... (GuruFocus.com)
Oct-04-24 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 04:05PM	Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024 (GlobeNewswire) -5.93% +10.81%
Aug-07-24 04:47PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance) -11.79%
04:01PM	Assertio Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-24-24 04:05PM	Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire) -6.17%

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schlessinger Sam	EVP, General Counsel	Feb 21 '26	Option Exercise	0.00	1,143	0	15,248	Feb 24 06:02 PM
Patel Ajay	EVP and CFO	Feb 21 '26	Option Exercise	0.00	1,143	0	16,508	Feb 24 06:01 PM
Schwichtenberg Paul	President and COO	Feb 21 '26	Option Exercise	0.00	1,143	0	14,553	Feb 24 06:01 PM
Schlessinger Sam	EVP, General Counsel	Feb 18 '26	Option Exercise	0.00	2,778	0	15,344	Feb 20 06:01 PM
Schwichtenberg Paul	President and COO	Feb 18 '26	Option Exercise	0.00	2,778	0	14,787	Feb 20 06:00 PM
Patel Ajay	EVP and CFO	Feb 18 '26	Option Exercise	0.00	2,778	0	16,742	Feb 20 06:00 PM
Schlessinger Sam	EVP, General Counsel	Feb 07 '26	Option Exercise	0.00	1,389	0	13,185	Feb 10 06:27 PM
Schwichtenberg Paul	President and COO	Feb 07 '26	Option Exercise	0.00	1,666	0	12,834	Feb 10 06:27 PM
Patel Ajay	EVP and CFO	Feb 07 '26	Option Exercise	0.00	1,666	0	14,789	Feb 10 06:26 PM
Stark David Matthew	Director	Nov 10 '25	Sale	0.76	8,959	6,806	98,541	Nov 12 06:00 PM
DAVID STARK	Director	Nov 10 '25	Proposed Sale	0.76	8,959	6,806		Nov 10 04:07 PM
O'Grady Brendan P.	CEO	May 31 '25	Option Exercise	0.00	166,665	0	178,371	Jun 03 06:00 PM
Schlessinger Sam	EVP, General Counsel	May 12 '25	Option Exercise	0.00	38,017	0	191,906	May 14 06:03 PM
Schwichtenberg Paul	See Remarks	May 12 '25	Option Exercise	0.00	38,017	0	184,362	May 14 06:01 PM
Patel Ajay	EVP and CFO	May 12 '25	Option Exercise	0.00	38,017	0	213,692	May 14 06:00 PM

RGEN

Repligen Corp

ASRT

Assertio Holdings Inc

Upgrade your Finviz experience